CAR-T therapies

News

FDA sets November review date for J&J's multiple myeloma CAR...

Johnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), narrowing the lead for Bristol-Myers Squibb and bluebi

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen files its first CAR-T therapy cilta-cel in Europe

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

Events

Partner Content

BCMA Targeted Therapies Summit

Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused

FDA sets November review date for J&J's multiple myeloma CAR...

Janssen files its first CAR-T therapy cilta-cel in Europe

BCMA Targeted Therapies Summit

Precision Neuro breaks new ground in BCI technology

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks